DRAFT LCD Reference Article Billing and Coding Article

Billing and Coding: Allergy Diagnostic Testing

DA60361

Expand All | Collapse All
Links in PDF documents are not guaranteed to work. To follow a web link, please use the MCD Website.
Draft Article
Draft Articles are works in progress and not necessarily a reflection of the current billing and coding practices. Revisions to codes are carefully and thoroughly reviewed and are not intended to change the original intent of the LCD.

Document Note

Note History

Contractor Information

Draft Article Information

General Information

Source Article ID
N/A
Draft Article ID
DA60361
Original ICD-9 Article ID
Not Applicable
Draft Article Title
Billing and Coding: Allergy Diagnostic Testing
Article Type
Billing and Coding
Original Effective Date
N/A
Revision Effective Date
N/A
Revision Ending Date
N/A
Retirement Date
N/A

CPT codes, descriptions, and other data only are copyright 2025 American Medical Association. All Rights Reserved. Fee schedules, relative value units, conversion factors and/or related components are not assigned by the AMA, are not part of CPT, and the AMA is not recommending their use. The AMA does not directly or indirectly practice medicine or dispense medical services. The AMA assumes no liability for data contained or not contained herein. CPT is a registered trademark of the American Medical Association.

Current Dental Terminology © 2025 American Dental Association. All rights reserved.

Copyright © 2025, the American Hospital Association, Chicago, Illinois. Reproduced with permission. No portion of the AHA copyrighted materials contained within this publication may be copied without the express written consent of the AHA. AHA copyrighted materials including the UB‐04 codes and descriptions may not be removed, copied, or utilized within any software, product, service, solution, or derivative work without the written consent of the AHA. If an entity wishes to utilize any AHA materials, please contact the AHA at ub04@aha.org or 312‐422‐3366.

Making copies or utilizing the content of the UB‐04 Manual, including the codes and/or descriptions, for internal purposes, resale and/or to be used in any product or publication; creating any modified or derivative work of the UB‐04 Manual and/or codes and descriptions; and/or making any commercial use of UB‐04 Manual or any portion thereof, including the codes and/or descriptions, is only authorized with an express license from the American Hospital Association. The American Hospital Association (the "AHA") has not reviewed, and is not responsible for, the completeness or accuracy of any information contained in this material, nor was the AHA or any of its affiliates, involved in the preparation of this material, or the analysis of information provided in the material. The views and/or positions presented in the material do not necessarily represent the views of the AHA. CMS and its products and services are not endorsed by the AHA or any of its affiliates.

CMS National Coverage Policy

Title XVIII of the Social Security Act, Section 1833 (e) prohibits Medicare payment for any claim which lacks the necessary information to process the claim.

Title XVIII of the Social Security Act, Section 1862 (a) (1) (A) allows coverage and payment of those items or services that are considered to be medically reasonable and necessary for the diagnosis or treatment of illness or injury or to improve the functioning of a malformed body member.

Title XVIII of the Social Security Act, Section 1862 (a) (1) (D) excludes investigational or experimental from Medicare coverage.

Title XVIII of the Social Security Act, Section 1862 (a)(7). This section excludes routine physical examinations.

42 U.S. Code § 263a

42 CFR, Section 410.20 – Physicians’ Services

42 CFR Section, 410.32(a) tests not ordered by the physician or other qualified non-physician provider who is treating the patient are not reasonable and necessary. (See 42 CFR 411.15(k)(1).

42 CFR, Section 410.32(b) diagnostic tests must be furnished under the appropriate level of supervision by a physician. Services furnished without the required level of supervision are not reasonable and necessary.

42 CFR 493.3 Applicability

CMS Pub 100-02 Medicare Benefit Policy Manual, Chapter 15 – Covered Medical and Other Health Services, Sections
20.2 – Physician Expense for Allergy Treatment
80.1 – Clinical Laboratory Services
80.6 – Requirements for Ordering and Following Orders for Diagnostic Tests

CMS Pub 100-03 Medicare National Coverage Determinations (NCD) Manual, Chapter 1 – Coverage Determinations, Part 2, Sections
110.9 – Antigens Prepared for Sublingual Administration
110.11 – Food Allergy Testing and Treatment
110.12 – Challenge Ingestion Food Testing
110.13 – Cytotoxic Food Tests

CMS Pub 100-04 Medicare Claims Processing Manual, Chapter 12 – Physicians/Nonphysician Practitioners, Section
200 - Allergy Testing and Immunotherapy

Chapter 16 – Laboratory Services, Section 40.7 – Billing for Noncovered Clinical Laboratory Tests

CMS Pub. 100-08 Medicare Program Integrity Manual, Chapter 3, section 3.6.2.2 Reasonable and Necessary Criteria

Centers for Medicare & Medicaid Services (CMS), Medicare National Correct Coding Initiative (NCCI) Policy Manual for Medicare Services, Chapter 11, Section K and V.  

Article Guidance

Article Text

The following coding and billing guidance is to be used with its associated Local coverage determination.

Documentation Requirements:

  1. All documentation must be maintained in the patient's medical record and made available to the contractor upon request.
  2. Every page of the record must be legible and include appropriate patient identification information (e.g., complete name, dates of service[s]). The documentation must include the legible signature of the physician or non-physician practitioner responsible for and providing the care to the patient.
  3. The medical record must support the use of the selected ICD-10-CM code(s). The submitted CPT/HCPCS code must describe the service performed.
  4. Prior to performance of allergy testing, there must be evidence in the medical record that a history has been obtained, indicating the possible presence of allergy.
    • This history should support that attempts to narrow the area of investigation were taken so that the minimal number of necessary skin tests might deliver a diagnosis.
    • The history should support that the selection of antigens was based on the patient specific history and physician examination.
  1. The medical record must indicate which allergy test(s) were used, the interpretation(s), and measurement (in mm) of reaction size of both wheal and erythema response or a standardized grading system in vivo testing (as applicable).

Utilization Guidelines (please see related LCD for reasonable and necessary guidelines)

  1. Inhalant allergy evaluation may require up to 70 percutaneous tests and up to 40 intracutaneous tests if percutaneous tests are negative.
  2. Patch tests may require up to 80 tests.
  3. Routine repeat skin testing is not considered reasonable and necessary unless documentation supports the need (e.g., changes in environmental exposure, new clinical signs/symptoms, lack of efficacy of current immunotherapy).
  4. The total number of tests, i.e. prick or intracutaneous, should not exceed generally accepted standards of testing set forth by professional associations. Exceeding these parameters may be justified if preliminary testing failed and immunotherapy failed to control symptoms. In this case, documentation of medical necessity is warranted.
  5. In-vitro testing performed in addition to skin testing for the same antigen is not usually necessary, except in the case of suspected latex sensitivity, Hymenoptera, or nut/peanut sensitivity where both the skin test and the in-vitro test may be performed.
  6. Allergy testing for substances such as newsprint, sugar, cornstarch, orris root, tobacco smoke, cotton, formaldehyde, and smog is not supported by evidence and hence is not covered.
  7. Payment for all serum lab testing requires performance in CLIA (Clinical Laboratory Improvement Amendments of 1988) certified laboratories. (42 CFR 493.3)
  8. If percutaneous or intracutaneous (intradermal) single test (CPT codes 95004 or 95024) and “sequential and incremental” tests (CPT codes 95017, 95018, or 95027) are performed on the same date of service, both the “sequential and incremental” test and single test codes may be reported if the tests are for different allergens or different dilutions of the same allergen. The unit of service to report is the number of separate tests. A single test and a “sequential and incremental” test for the same dilution of an allergen shall not be reported separately on the same date of service. For example, if the single test for an antigen is positive and the physician proceeds to “sequential and incremental” tests with 3 additional different dilutions of the same antigen, the provider/supplier may report 1 unit of service for the single test code and 3 UOS for the “sequential and incremental” test code.
  9. Some allergy testing CPT codes (e.g., 95004, 95017-95052) are reported based on the number of individual tests performed. CMS payment policy does not allow including testing of positive or negative controls in the number of tests reported. For example, if percutaneous testing (CPT code 95018) with penicillin allergens administering 6 allergens plus a positive and negative control is performed, only 6 tests may be reported for CPT code 95018.
  10. CPT codes for allergy testing and immunotherapy are generally not reported on the same date of service unless the physician provides allergy immunotherapy and testing for additional allergens on the same day.
  11. Physicians shall not report allergy testing CPT codes for allergen potency (safety) testing prior to administration of immunotherapy. Confirmation of the appropriate potency of an allergen vial for immunotherapy is an inherent component of immunotherapy.
  12. Consistent with the related LCD, CPT code 82785 Gammaglobulin [immunoglobulin]; IgE is not appropriate in most general allergy testing. Please refer to the LCD for details on medically reasonable and necessary guidelines. 

Response To Comments

Number Comment Response
1
N/A

Coding Information

Bill Type Codes

Code Description

Please accept the License to see the codes.

N/A

Revenue Codes

Code Description

Please accept the License to see the codes.

N/A

CPT/HCPCS Codes

Please accept the License to see the codes.

N/A

CPT/HCPCS Modifiers

Group 1

Group 1 Paragraph

N/A

Group 1 Codes

N/A

N/A

ICD-10-CM Codes that Support Medical Necessity

Group 1

(376 Codes)
Group 1 Paragraph

The following ICD-10-CM codes support medical necessity and provide coverage for CPT codes: 95004, 95017, 95018, 95024, 95027, 95028, 95060, 95065, 95070, 82785, 86003, and 86008.

Group 1 Codes
Code Description
B44.81 Allergic bronchopulmonary aspergillosis
H10.411 Chronic giant papillary conjunctivitis, right eye
H10.412 Chronic giant papillary conjunctivitis, left eye
H10.413 Chronic giant papillary conjunctivitis, bilateral
H10.44 Vernal conjunctivitis
H10.45 Other chronic allergic conjunctivitis
H16.261 Vernal keratoconjunctivitis, with limbar and corneal involvement, right eye
H16.262 Vernal keratoconjunctivitis, with limbar and corneal involvement, left eye
H16.263 Vernal keratoconjunctivitis, with limbar and corneal involvement, bilateral
H65.04 Acute serous otitis media, recurrent, right ear
H65.05 Acute serous otitis media, recurrent, left ear
H65.06 Acute serous otitis media, recurrent, bilateral
H65.111 Acute and subacute allergic otitis media (mucoid) (sanguinous) (serous), right ear
H65.112 Acute and subacute allergic otitis media (mucoid) (sanguinous) (serous), left ear
H65.113 Acute and subacute allergic otitis media (mucoid) (sanguinous) (serous), bilateral
H65.114 Acute and subacute allergic otitis media (mucoid) (sanguinous) (serous), recurrent, right ear
H65.115 Acute and subacute allergic otitis media (mucoid) (sanguinous) (serous), recurrent, left ear
H65.116 Acute and subacute allergic otitis media (mucoid) (sanguinous) (serous), recurrent, bilateral
H65.21 Chronic serous otitis media, right ear
H65.22 Chronic serous otitis media, left ear
H65.23 Chronic serous otitis media, bilateral
H65.411 Chronic allergic otitis media, right ear
H65.412 Chronic allergic otitis media, left ear
H65.413 Chronic allergic otitis media, bilateral
H65.491 Other chronic nonsuppurative otitis media, right ear
H65.492 Other chronic nonsuppurative otitis media, left ear
H65.493 Other chronic nonsuppurative otitis media, bilateral
H68.012 Acute Eustachian salpingitis, left ear
H68.022 Chronic Eustachian salpingitis, left ear
H68.023 Chronic Eustachian salpingitis, bilateral
J01.01 Acute recurrent maxillary sinusitis
J01.11 Acute recurrent frontal sinusitis
J01.21 Acute recurrent ethmoidal sinusitis
J01.31 Acute recurrent sphenoidal sinusitis
J01.41 Acute recurrent pansinusitis
J01.81 Other acute recurrent sinusitis
J30.0 Vasomotor rhinitis
J30.1 Allergic rhinitis due to pollen
J30.2 Other seasonal allergic rhinitis
J30.5 Allergic rhinitis due to food
J30.81 Allergic rhinitis due to animal (cat) (dog) hair and dander
J30.89 Other allergic rhinitis
J31.0 Chronic rhinitis
J31.1 Chronic nasopharyngitis
J32.0 Chronic maxillary sinusitis
J32.1 Chronic frontal sinusitis
J32.2 Chronic ethmoidal sinusitis
J32.3 Chronic sphenoidal sinusitis
J33.0 Polyp of nasal cavity
J33.8 Other polyp of sinus
J45.20 Mild intermittent asthma, uncomplicated
J45.21 Mild intermittent asthma with (acute) exacerbation
J45.22 Mild intermittent asthma with status asthmaticus
J45.30 Mild persistent asthma, uncomplicated
J45.31 Mild persistent asthma with (acute) exacerbation
J45.32 Mild persistent asthma with status asthmaticus
J45.40 Moderate persistent asthma, uncomplicated
J45.41 Moderate persistent asthma with (acute) exacerbation
J45.42 Moderate persistent asthma with status asthmaticus
J45.50 Severe persistent asthma, uncomplicated
J45.51 Severe persistent asthma with (acute) exacerbation
J45.52 Severe persistent asthma with status asthmaticus
J45.901 Unspecified asthma with (acute) exacerbation
J45.902 Unspecified asthma with status asthmaticus
J45.909 Unspecified asthma, uncomplicated
J45.991 Cough variant asthma
J45.998 Other asthma
K20.0 Eosinophilic esophagitis
L20.0 Besnier's prurigo
L20.81 Atopic neurodermatitis
L20.82 Flexural eczema
L20.84 Intrinsic (allergic) eczema
L20.89 Other atopic dermatitis
L23.3 Allergic contact dermatitis due to drugs in contact with skin
L23.7 Allergic contact dermatitis due to plants, except food
L23.81 Allergic contact dermatitis due to animal (cat) (dog) dander
L27.0 Generalized skin eruption due to drugs and medicaments taken internally
L27.1 Localized skin eruption due to drugs and medicaments taken internally
L27.2 Dermatitis due to ingested food
L27.8 Dermatitis due to other substances taken internally
L27.9 Dermatitis due to unspecified substance taken internally
L50.0 Allergic urticaria
L50.1 Idiopathic urticaria
L50.3 Dermatographic urticaria
L50.6 Contact urticaria
L50.8 Other urticaria
R06.02 Shortness of breath
R06.09 Other forms of dyspnea
R06.2 Wheezing
R09.81 Nasal congestion
R21 Rash and other nonspecific skin eruption
T36.0X5A Adverse effect of penicillins, initial encounter
T36.0X5D Adverse effect of penicillins, subsequent encounter
T36.0X5S Adverse effect of penicillins, sequela
T36.1X5A Adverse effect of cephalosporins and other beta-lactam antibiotics, initial encounter
T36.1X5D Adverse effect of cephalosporins and other beta-lactam antibiotics, subsequent encounter
T36.1X5S Adverse effect of cephalosporins and other beta-lactam antibiotics, sequela
T36.3X5A Adverse effect of macrolides, initial encounter
T36.3X5D Adverse effect of macrolides, subsequent encounter
T36.3X5S Adverse effect of macrolides, sequela
T36.4X5A Adverse effect of tetracyclines, initial encounter
T36.4X5D Adverse effect of tetracyclines, subsequent encounter
T36.4X5S Adverse effect of tetracyclines, sequela
T36.5X5A Adverse effect of aminoglycosides, initial encounter
T36.5X5D Adverse effect of aminoglycosides, subsequent encounter
T36.5X5S Adverse effect of aminoglycosides, sequela
T36.6X5A Adverse effect of rifampicins, initial encounter
T36.6X5D Adverse effect of rifampicins, subsequent encounter
T36.6X5S Adverse effect of rifampicins, sequela
T36.7X5A Adverse effect of antifungal antibiotics, systemically used, initial encounter
T36.7X5D Adverse effect of antifungal antibiotics, systemically used, subsequent encounter
T36.7X5S Adverse effect of antifungal antibiotics, systemically used, sequela
T36.8X5A Adverse effect of other systemic antibiotics, initial encounter
T36.8X5D Adverse effect of other systemic antibiotics, subsequent encounter
T36.8X5S Adverse effect of other systemic antibiotics, sequela
T37.0X5A Adverse effect of sulfonamides, initial encounter
T37.0X5D Adverse effect of sulfonamides, subsequent encounter
T37.0X5S Adverse effect of sulfonamides, sequela
T39.015A Adverse effect of aspirin, initial encounter
T39.015D Adverse effect of aspirin, subsequent encounter
T39.015S Adverse effect of aspirin, sequela
T39.095A Adverse effect of salicylates, initial encounter
T39.095D Adverse effect of salicylates, subsequent encounter
T39.095S Adverse effect of salicylates, sequela
T39.395A Adverse effect of other nonsteroidal anti-inflammatory drugs [NSAID], initial encounter
T39.395D Adverse effect of other nonsteroidal anti-inflammatory drugs [NSAID], subsequent encounter
T39.395S Adverse effect of other nonsteroidal anti-inflammatory drugs [NSAID], sequela
T41.3X5A Adverse effect of local anesthetics, initial encounter
T41.3X5D Adverse effect of local anesthetics, subsequent encounter
T41.3X5S Adverse effect of local anesthetics, sequela
T50.A15A Adverse effect of pertussis vaccine, including combinations with a pertussis component, initial encounter
T50.A15D Adverse effect of pertussis vaccine, including combinations with a pertussis component, subsequent encounter
T50.A15S Adverse effect of pertussis vaccine, including combinations with a pertussis component, sequela
T50.A25A Adverse effect of mixed bacterial vaccines without a pertussis component, initial encounter
T50.A25D Adverse effect of mixed bacterial vaccines without a pertussis component, subsequent encounter
T50.A25S Adverse effect of mixed bacterial vaccines without a pertussis component, sequela
T50.A95A Adverse effect of other bacterial vaccines, initial encounter
T50.A95D Adverse effect of other bacterial vaccines, subsequent encounter
T50.A95S Adverse effect of other bacterial vaccines, sequela
T50.B15A Adverse effect of smallpox vaccines, initial encounter
T50.B15D Adverse effect of smallpox vaccines, subsequent encounter
T50.B15S Adverse effect of smallpox vaccines, sequela
T50.B95A Adverse effect of other viral vaccines, initial encounter
T50.B95D Adverse effect of other viral vaccines, subsequent encounter
T50.B95S Adverse effect of other viral vaccines, sequela
T50.Z95A Adverse effect of other vaccines and biological substances, initial encounter
T50.Z95D Adverse effect of other vaccines and biological substances, subsequent encounter
T50.Z95S Adverse effect of other vaccines and biological substances, sequela
T50.915A Adverse effect of multiple unspecified drugs, medicaments and biological substances, initial encounter
T50.915D Adverse effect of multiple unspecified drugs, medicaments and biological substances, subsequent encounter
T50.915S Adverse effect of multiple unspecified drugs, medicaments and biological substances, sequela
T50.995A Adverse effect of other drugs, medicaments and biological substances, initial encounter
T50.995D Adverse effect of other drugs, medicaments and biological substances, subsequent encounter
T50.995S Adverse effect of other drugs, medicaments and biological substances, sequela
T63.001A Toxic effect of unspecified snake venom, accidental (unintentional), initial encounter
T63.001D Toxic effect of unspecified snake venom, accidental (unintentional), subsequent encounter
T63.001S Toxic effect of unspecified snake venom, accidental (unintentional), sequela
T63.004A Toxic effect of unspecified snake venom, undetermined, initial encounter
T63.004D Toxic effect of unspecified snake venom, undetermined, subsequent encounter
T63.004S Toxic effect of unspecified snake venom, undetermined, sequela
T63.011A Toxic effect of rattlesnake venom, accidental (unintentional), initial encounter
T63.011D Toxic effect of rattlesnake venom, accidental (unintentional), subsequent encounter
T63.011S Toxic effect of rattlesnake venom, accidental (unintentional), sequela
T63.014A Toxic effect of rattlesnake venom, undetermined, initial encounter
T63.014D Toxic effect of rattlesnake venom, undetermined, subsequent encounter
T63.014S Toxic effect of rattlesnake venom, undetermined, sequela
T63.021A Toxic effect of coral snake venom, accidental (unintentional), initial encounter
T63.021D Toxic effect of coral snake venom, accidental (unintentional), subsequent encounter
T63.021S Toxic effect of coral snake venom, accidental (unintentional), sequela
T63.024A Toxic effect of coral snake venom, undetermined, initial encounter
T63.024D Toxic effect of coral snake venom, undetermined, subsequent encounter
T63.024S Toxic effect of coral snake venom, undetermined, sequela
T63.031A Toxic effect of taipan venom, accidental (unintentional), initial encounter
T63.031D Toxic effect of taipan venom, accidental (unintentional), subsequent encounter
T63.031S Toxic effect of taipan venom, accidental (unintentional), sequela
T63.034A Toxic effect of taipan venom, undetermined, initial encounter
T63.034D Toxic effect of taipan venom, undetermined, subsequent encounter
T63.034S Toxic effect of taipan venom, undetermined, sequela
T63.041A Toxic effect of cobra venom, accidental (unintentional), initial encounter
T63.041D Toxic effect of cobra venom, accidental (unintentional), subsequent encounter
T63.041S Toxic effect of cobra venom, accidental (unintentional), sequela
T63.044A Toxic effect of cobra venom, undetermined, initial encounter
T63.044D Toxic effect of cobra venom, undetermined, subsequent encounter
T63.044S Toxic effect of cobra venom, undetermined, sequela
T63.061A Toxic effect of venom of other North and South American snake, accidental (unintentional), initial encounter
T63.061D Toxic effect of venom of other North and South American snake, accidental (unintentional), subsequent encounter
T63.061S Toxic effect of venom of other North and South American snake, accidental (unintentional), sequela
T63.064A Toxic effect of venom of other North and South American snake, undetermined, initial encounter
T63.064D Toxic effect of venom of other North and South American snake, undetermined, subsequent encounter
T63.064S Toxic effect of venom of other North and South American snake, undetermined, sequela
T63.071A Toxic effect of venom of other Australian snake, accidental (unintentional), initial encounter
T63.071D Toxic effect of venom of other Australian snake, accidental (unintentional), subsequent encounter
T63.071S Toxic effect of venom of other Australian snake, accidental (unintentional), sequela
T63.074A Toxic effect of venom of other Australian snake, undetermined, initial encounter
T63.074D Toxic effect of venom of other Australian snake, undetermined, subsequent encounter
T63.074S Toxic effect of venom of other Australian snake, undetermined, sequela
T63.081A Toxic effect of venom of other African and Asian snake, accidental (unintentional), initial encounter
T63.081D Toxic effect of venom of other African and Asian snake, accidental (unintentional), subsequent encounter
T63.081S Toxic effect of venom of other African and Asian snake, accidental (unintentional), sequela
T63.084A Toxic effect of venom of other African and Asian snake, undetermined, initial encounter
T63.084D Toxic effect of venom of other African and Asian snake, undetermined, subsequent encounter
T63.084S Toxic effect of venom of other African and Asian snake, undetermined, sequela
T63.091A Toxic effect of venom of other snake, accidental (unintentional), initial encounter
T63.091D Toxic effect of venom of other snake, accidental (unintentional), subsequent encounter
T63.091S Toxic effect of venom of other snake, accidental (unintentional), sequela
T63.094A Toxic effect of venom of other snake, undetermined, initial encounter
T63.094D Toxic effect of venom of other snake, undetermined, subsequent encounter
T63.094S Toxic effect of venom of other snake, undetermined, sequela
T63.111A Toxic effect of venom of gila monster, accidental (unintentional), initial encounter
T63.111D Toxic effect of venom of gila monster, accidental (unintentional), subsequent encounter
T63.111S Toxic effect of venom of gila monster, accidental (unintentional), sequela
T63.114A Toxic effect of venom of gila monster, undetermined, initial encounter
T63.114D Toxic effect of venom of gila monster, undetermined, subsequent encounter
T63.114S Toxic effect of venom of gila monster, undetermined, sequela
T63.121A Toxic effect of venom of other venomous lizard, accidental (unintentional), initial encounter
T63.121D Toxic effect of venom of other venomous lizard, accidental (unintentional), subsequent encounter
T63.121S Toxic effect of venom of other venomous lizard, accidental (unintentional), sequela
T63.124A Toxic effect of venom of other venomous lizard, undetermined, initial encounter
T63.124D Toxic effect of venom of other venomous lizard, undetermined, subsequent encounter
T63.124S Toxic effect of venom of other venomous lizard, undetermined, sequela
T63.191A Toxic effect of venom of other reptiles, accidental (unintentional), initial encounter
T63.191D Toxic effect of venom of other reptiles, accidental (unintentional), subsequent encounter
T63.191S Toxic effect of venom of other reptiles, accidental (unintentional), sequela
T63.194A Toxic effect of venom of other reptiles, undetermined, initial encounter
T63.194D Toxic effect of venom of other reptiles, undetermined, subsequent encounter
T63.194S Toxic effect of venom of other reptiles, undetermined, sequela
T63.2X1A Toxic effect of venom of scorpion, accidental (unintentional), initial encounter
T63.2X1D Toxic effect of venom of scorpion, accidental (unintentional), subsequent encounter
T63.2X1S Toxic effect of venom of scorpion, accidental (unintentional), sequela
T63.2X4A Toxic effect of venom of scorpion, undetermined, initial encounter
T63.2X4D Toxic effect of venom of scorpion, undetermined, subsequent encounter
T63.2X4S Toxic effect of venom of scorpion, undetermined, sequela
T63.301A Toxic effect of unspecified spider venom, accidental (unintentional), initial encounter
T63.301D Toxic effect of unspecified spider venom, accidental (unintentional), subsequent encounter
T63.301S Toxic effect of unspecified spider venom, accidental (unintentional), sequela
T63.304A Toxic effect of unspecified spider venom, undetermined, initial encounter
T63.304D Toxic effect of unspecified spider venom, undetermined, subsequent encounter
T63.304S Toxic effect of unspecified spider venom, undetermined, sequela
T63.311A Toxic effect of venom of black widow spider, accidental (unintentional), initial encounter
T63.311D Toxic effect of venom of black widow spider, accidental (unintentional), subsequent encounter
T63.311S Toxic effect of venom of black widow spider, accidental (unintentional), sequela
T63.314A Toxic effect of venom of black widow spider, undetermined, initial encounter
T63.314D Toxic effect of venom of black widow spider, undetermined, subsequent encounter
T63.314S Toxic effect of venom of black widow spider, undetermined, sequela
T63.321A Toxic effect of venom of tarantula, accidental (unintentional), initial encounter
T63.321D Toxic effect of venom of tarantula, accidental (unintentional), subsequent encounter
T63.321S Toxic effect of venom of tarantula, accidental (unintentional), sequela
T63.324A Toxic effect of venom of tarantula, undetermined, initial encounter
T63.324D Toxic effect of venom of tarantula, undetermined, subsequent encounter
T63.324S Toxic effect of venom of tarantula, undetermined, sequela
T63.331A Toxic effect of venom of brown recluse spider, accidental (unintentional), initial encounter
T63.331D Toxic effect of venom of brown recluse spider, accidental (unintentional), subsequent encounter
T63.331S Toxic effect of venom of brown recluse spider, accidental (unintentional), sequela
T63.334A Toxic effect of venom of brown recluse spider, undetermined, initial encounter
T63.334D Toxic effect of venom of brown recluse spider, undetermined, subsequent encounter
T63.334S Toxic effect of venom of brown recluse spider, undetermined, sequela
T63.391A Toxic effect of venom of other spider, accidental (unintentional), initial encounter
T63.391D Toxic effect of venom of other spider, accidental (unintentional), subsequent encounter
T63.391S Toxic effect of venom of other spider, accidental (unintentional), sequela
T63.394A Toxic effect of venom of other spider, undetermined, initial encounter
T63.394D Toxic effect of venom of other spider, undetermined, subsequent encounter
T63.394S Toxic effect of venom of other spider, undetermined, sequela
T63.411A Toxic effect of venom of centipedes and venomous millipedes, accidental (unintentional), initial encounter
T63.411D Toxic effect of venom of centipedes and venomous millipedes, accidental (unintentional), subsequent encounter
T63.411S Toxic effect of venom of centipedes and venomous millipedes, accidental (unintentional), sequela
T63.414A Toxic effect of venom of centipedes and venomous millipedes, undetermined, initial encounter
T63.414D Toxic effect of venom of centipedes and venomous millipedes, undetermined, subsequent encounter
T63.414S Toxic effect of venom of centipedes and venomous millipedes, undetermined, sequela
T63.421A Toxic effect of venom of ants, accidental (unintentional), initial encounter
T63.421D Toxic effect of venom of ants, accidental (unintentional), subsequent encounter
T63.421S Toxic effect of venom of ants, accidental (unintentional), sequela
T63.424A Toxic effect of venom of ants, undetermined, initial encounter
T63.424D Toxic effect of venom of ants, undetermined, subsequent encounter
T63.424S Toxic effect of venom of ants, undetermined, sequela
T63.441A Toxic effect of venom of bees, accidental (unintentional), initial encounter
T63.441D Toxic effect of venom of bees, accidental (unintentional), subsequent encounter
T63.441S Toxic effect of venom of bees, accidental (unintentional), sequela
T63.444A Toxic effect of venom of bees, undetermined, initial encounter
T63.444D Toxic effect of venom of bees, undetermined, subsequent encounter
T63.444S Toxic effect of venom of bees, undetermined, sequela
T63.451A Toxic effect of venom of hornets, accidental (unintentional), initial encounter
T63.451D Toxic effect of venom of hornets, accidental (unintentional), subsequent encounter
T63.451S Toxic effect of venom of hornets, accidental (unintentional), sequela
T63.454A Toxic effect of venom of hornets, undetermined, initial encounter
T63.454D Toxic effect of venom of hornets, undetermined, subsequent encounter
T63.454S Toxic effect of venom of hornets, undetermined, sequela
T63.461A Toxic effect of venom of wasps, accidental (unintentional), initial encounter
T63.461D Toxic effect of venom of wasps, accidental (unintentional), subsequent encounter
T63.461S Toxic effect of venom of wasps, accidental (unintentional), sequela
T63.464A Toxic effect of venom of wasps, undetermined, initial encounter
T63.464D Toxic effect of venom of wasps, undetermined, subsequent encounter
T63.464S Toxic effect of venom of wasps, undetermined, sequela
T63.481A Toxic effect of venom of other arthropod, accidental (unintentional), initial encounter
T63.481D Toxic effect of venom of other arthropod, accidental (unintentional), subsequent encounter
T63.481S Toxic effect of venom of other arthropod, accidental (unintentional), sequela
T63.484A Toxic effect of venom of other arthropod, undetermined, initial encounter
T63.484D Toxic effect of venom of other arthropod, undetermined, subsequent encounter
T63.484S Toxic effect of venom of other arthropod, undetermined, sequela
T65.811A Toxic effect of latex, accidental (unintentional), initial encounter
T65.811D Toxic effect of latex, accidental (unintentional), subsequent encounter
T65.811S Toxic effect of latex, accidental (unintentional), sequela
T65.814A Toxic effect of latex, undetermined, initial encounter
T65.814D Toxic effect of latex, undetermined, subsequent encounter
T65.814S Toxic effect of latex, undetermined, sequela
T78.01XA Anaphylactic reaction due to peanuts, initial encounter
T78.01XD Anaphylactic reaction due to peanuts, subsequent encounter
T78.01XS Anaphylactic reaction due to peanuts, sequela
T78.02XA Anaphylactic reaction due to shellfish (crustaceans), initial encounter
T78.02XD Anaphylactic reaction due to shellfish (crustaceans), subsequent encounter
T78.02XS Anaphylactic reaction due to shellfish (crustaceans), sequela
T78.03XA Anaphylactic reaction due to other fish, initial encounter
T78.03XD Anaphylactic reaction due to other fish, subsequent encounter
T78.03XS Anaphylactic reaction due to other fish, sequela
T78.04XA Anaphylactic reaction due to fruits and vegetables, initial encounter
T78.04XD Anaphylactic reaction due to fruits and vegetables, subsequent encounter
T78.04XS Anaphylactic reaction due to fruits and vegetables, sequela
T78.05XA Anaphylactic reaction due to tree nuts and seeds, initial encounter
T78.05XD Anaphylactic reaction due to tree nuts and seeds, subsequent encounter
T78.05XS Anaphylactic reaction due to tree nuts and seeds, sequela
T78.06XA Anaphylactic reaction due to food additives, initial encounter
T78.06XD Anaphylactic reaction due to food additives, subsequent encounter
T78.06XS Anaphylactic reaction due to food additives, sequela
T78.070A Anaphylactic reaction due to milk and dairy products with tolerance to baked milk, initial encounter
T78.070D Anaphylactic reaction due to milk and dairy products with tolerance to baked milk, subsequent encounter
T78.070S Anaphylactic reaction due to milk and dairy products with tolerance to baked milk, sequela
T78.071A Anaphylactic reaction due to milk and dairy products with reactivity to baked milk, initial encounter
T78.071D Anaphylactic reaction due to milk and dairy products with reactivity to baked milk, subsequent encounter
T78.071S Anaphylactic reaction due to milk and dairy products with reactivity to baked milk, sequela
T78.079A Anaphylactic reaction due to milk and dairy products, unspecified, initial encounter
T78.079D Anaphylactic reaction due to milk and dairy products, unspecified, subsequent encounter
T78.079S Anaphylactic reaction due to milk and dairy products, unspecified, sequela
T78.080A Anaphylactic reaction due to egg with tolerance to baked egg, initial encounter
T78.080D Anaphylactic reaction due to egg with tolerance to baked egg, subsequent encounter
T78.080S Anaphylactic reaction due to egg with tolerance to baked egg, sequela
T78.081A Anaphylactic reaction due to egg with reactivity to baked egg, initial encounter
T78.081D Anaphylactic reaction due to egg with reactivity to baked egg, subsequent encounter
T78.081S Anaphylactic reaction due to egg with reactivity to baked egg, sequela
T78.089A Anaphylactic reaction due to eggs, unspecified, initial encounter
T78.089D Anaphylactic reaction due to eggs, unspecified, subsequent encounter
T78.089S Anaphylactic reaction due to eggs, unspecified, sequela
T78.09XA Anaphylactic reaction due to other food products, initial encounter
T78.09XD Anaphylactic reaction due to other food products, subsequent encounter
T78.09XS Anaphylactic reaction due to other food products, sequela
T78.110A Other adverse food reactions due to milk and dairy products with tolerance to baked milk, initial encounter
T78.110D Other adverse food reactions due to milk and dairy products with tolerance to baked milk, subsequent encounter
T78.110S Other adverse food reactions due to milk and dairy products with tolerance to baked milk, sequela
T78.111A Other adverse food reaction due to milk and dairy products with reactivity to baked milk, initial encounter
T78.111D Other adverse food reaction due to milk and dairy products with reactivity to baked milk, subsequent encounter
T78.111S Other adverse food reaction due to milk and dairy products with reactivity to baked milk, sequela
T78.119A Other adverse food reaction due to milk and dairy products with baked milk tolerance/reactivity, unspecified, initial encounter
T78.119D Other adverse food reaction due to milk and dairy products with baked milk tolerance/reactivity, unspecified, subsequent encounter
T78.119S Other adverse food reaction due to milk and dairy products with baked milk tolerance/reactivity, unspecified, sequela
T78.120A Other adverse food reaction due to egg with tolerance to baked egg, initial encounter
T78.120D Other adverse food reaction due to egg with tolerance to baked egg, subsequent encounter
T78.120S Other adverse food reaction due to egg with tolerance to baked egg, sequela
T78.121A Other adverse food reaction due to egg with reactivity to baked egg, initial encounter
T78.121D Other adverse food reaction due to egg with reactivity to baked egg, subsequent encounter
T78.121S Other adverse food reaction due to egg with reactivity to baked egg, sequela
T78.129A Other adverse food reaction due to egg with baked egg tolerance/reactivity, unspecified, initial encounter
T78.129D Other adverse food reaction due to egg with baked egg tolerance/reactivity, unspecified, subsequent encounter
T78.129S Other adverse food reaction due to egg with baked egg tolerance/reactivity, unspecified, sequela
T78.3XXA Angioneurotic edema, initial encounter
T78.3XXD Angioneurotic edema, subsequent encounter
T78.3XXS Angioneurotic edema, sequela
T78.49XA Other allergy, initial encounter
T78.49XD Other allergy, subsequent encounter
T78.49XS Other allergy, sequela
T80.51XA Anaphylactic reaction due to administration of blood and blood products, initial encounter
T80.51XD Anaphylactic reaction due to administration of blood and blood products, subsequent encounter
T80.51XS Anaphylactic reaction due to administration of blood and blood products, sequela
T80.52XA Anaphylactic reaction due to vaccination, initial encounter
T80.52XD Anaphylactic reaction due to vaccination, subsequent encounter
T80.52XS Anaphylactic reaction due to vaccination, sequela
T88.6XXA Anaphylactic reaction due to adverse effect of correct drug or medicament properly administered, initial encounter
T88.6XXD Anaphylactic reaction due to adverse effect of correct drug or medicament properly administered, subsequent encounter
T88.6XXS Anaphylactic reaction due to adverse effect of correct drug or medicament properly administered, sequela

Group 2

(48 Codes)
Group 2 Paragraph

The following ICD-10-CM codes support medical necessity and provide coverage for CPT codes: 95044, 95052, and 95056.

Group 2 Codes
Code Description
E80.0 Hereditary erythropoietic porphyria
E80.1 Porphyria cutanea tarda
E80.21 Acute intermittent (hepatic) porphyria
E80.29 Other porphyria
L20.0 Besnier's prurigo
L20.81 Atopic neurodermatitis
L20.82 Flexural eczema
L20.84 Intrinsic (allergic) eczema
L20.89 Other atopic dermatitis
L23.0 Allergic contact dermatitis due to metals
L23.1 Allergic contact dermatitis due to adhesives
L23.2 Allergic contact dermatitis due to cosmetics
L23.3 Allergic contact dermatitis due to drugs in contact with skin
L23.4 Allergic contact dermatitis due to dyes
L23.5 Allergic contact dermatitis due to other chemical products
L23.6 Allergic contact dermatitis due to food in contact with the skin
L23.7 Allergic contact dermatitis due to plants, except food
L23.81 Allergic contact dermatitis due to animal (cat) (dog) dander
L23.89 Allergic contact dermatitis due to other agents
L24.0 Irritant contact dermatitis due to detergents
L24.1 Irritant contact dermatitis due to oils and greases
L24.2 Irritant contact dermatitis due to solvents
L24.3 Irritant contact dermatitis due to cosmetics
L24.4 Irritant contact dermatitis due to drugs in contact with skin
L24.5 Irritant contact dermatitis due to other chemical products
L24.6 Irritant contact dermatitis due to food in contact with skin
L24.7 Irritant contact dermatitis due to plants, except food
L24.81 Irritant contact dermatitis due to metals
L24.89 Irritant contact dermatitis due to other agents
L24.9 Irritant contact dermatitis, unspecified cause
L25.0 Unspecified contact dermatitis due to cosmetics
L25.1 Unspecified contact dermatitis due to drugs in contact with skin
L25.2 Unspecified contact dermatitis due to dyes
L25.3 Unspecified contact dermatitis due to other chemical products
L25.4 Unspecified contact dermatitis due to food in contact with skin
L25.5 Unspecified contact dermatitis due to plants, except food
L25.8 Unspecified contact dermatitis due to other agents
L30.0 Nummular dermatitis
L30.8 Other specified dermatitis
L56.0 Drug phototoxic response
L56.1 Drug photoallergic response
L56.2 Photocontact dermatitis [berloque dermatitis]
L56.3 Solar urticaria
L56.4 Polymorphous light eruption
L56.8 Other specified acute skin changes due to ultraviolet radiation
L57.1 Actinic reticuloid
L57.5 Actinic granuloma
L95.1 Erythema elevatum diutinum

Group 3

(481 Codes)
Group 3 Paragraph

The following ICD-10-CM codes support medical necessity and provide coverage for CPT codes: 95076 and 95079

Group 3 Codes
Code Description
L27.2 Dermatitis due to ingested food
T36.0X5A Adverse effect of penicillins, initial encounter
T36.0X5D Adverse effect of penicillins, subsequent encounter
T36.0X5S Adverse effect of penicillins, sequela
T36.1X5A Adverse effect of cephalosporins and other beta-lactam antibiotics, initial encounter
T36.1X5D Adverse effect of cephalosporins and other beta-lactam antibiotics, subsequent encounter
T36.1X5S Adverse effect of cephalosporins and other beta-lactam antibiotics, sequela
T36.2X5A Adverse effect of chloramphenicol group, initial encounter
T36.2X5D Adverse effect of chloramphenicol group, subsequent encounter
T36.2X5S Adverse effect of chloramphenicol group, sequela
T36.3X5A Adverse effect of macrolides, initial encounter
T36.3X5D Adverse effect of macrolides, subsequent encounter
T36.3X5S Adverse effect of macrolides, sequela
T36.4X5A Adverse effect of tetracyclines, initial encounter
T36.4X5D Adverse effect of tetracyclines, subsequent encounter
T36.4X5S Adverse effect of tetracyclines, sequela
T36.5X5A Adverse effect of aminoglycosides, initial encounter
T36.5X5D Adverse effect of aminoglycosides, subsequent encounter
T36.5X5S Adverse effect of aminoglycosides, sequela
T36.6X5A Adverse effect of rifampicins, initial encounter
T36.6X5D Adverse effect of rifampicins, subsequent encounter
T36.6X5S Adverse effect of rifampicins, sequela
T36.7X5A Adverse effect of antifungal antibiotics, systemically used, initial encounter
T36.7X5D Adverse effect of antifungal antibiotics, systemically used, subsequent encounter
T36.7X5S Adverse effect of antifungal antibiotics, systemically used, sequela
T36.8X5A Adverse effect of other systemic antibiotics, initial encounter
T36.8X5D Adverse effect of other systemic antibiotics, subsequent encounter
T36.8X5S Adverse effect of other systemic antibiotics, sequela
T37.0X5A Adverse effect of sulfonamides, initial encounter
T37.0X5D Adverse effect of sulfonamides, subsequent encounter
T37.0X5S Adverse effect of sulfonamides, sequela
T37.1X5A Adverse effect of antimycobacterial drugs, initial encounter
T37.1X5D Adverse effect of antimycobacterial drugs, subsequent encounter
T37.1X5S Adverse effect of antimycobacterial drugs, sequela
T37.2X5A Adverse effect of antimalarials and drugs acting on other blood protozoa, initial encounter
T37.2X5D Adverse effect of antimalarials and drugs acting on other blood protozoa, subsequent encounter
T37.2X5S Adverse effect of antimalarials and drugs acting on other blood protozoa, sequela
T37.3X5A Adverse effect of other antiprotozoal drugs, initial encounter
T37.3X5D Adverse effect of other antiprotozoal drugs, subsequent encounter
T37.3X5S Adverse effect of other antiprotozoal drugs, sequela
T37.4X5A Adverse effect of anthelminthics, initial encounter
T37.4X5D Adverse effect of anthelminthics, subsequent encounter
T37.4X5S Adverse effect of anthelminthics, sequela
T37.5X5A Adverse effect of antiviral drugs, initial encounter
T37.5X5D Adverse effect of antiviral drugs, subsequent encounter
T37.5X5S Adverse effect of antiviral drugs, sequela
T38.0X5A Adverse effect of glucocorticoids and synthetic analogues, initial encounter
T38.0X5D Adverse effect of glucocorticoids and synthetic analogues, subsequent encounter
T38.0X5S Adverse effect of glucocorticoids and synthetic analogues, sequela
T38.1X5A Adverse effect of thyroid hormones and substitutes, initial encounter
T38.1X5D Adverse effect of thyroid hormones and substitutes, subsequent encounter
T38.1X5S Adverse effect of thyroid hormones and substitutes, sequela
T38.2X5A Adverse effect of antithyroid drugs, initial encounter
T38.2X5D Adverse effect of antithyroid drugs, subsequent encounter
T38.2X5S Adverse effect of antithyroid drugs, sequela
T38.3X5A Adverse effect of insulin and oral hypoglycemic [antidiabetic] drugs, initial encounter
T38.3X5D Adverse effect of insulin and oral hypoglycemic [antidiabetic] drugs, subsequent encounter
T38.3X5S Adverse effect of insulin and oral hypoglycemic [antidiabetic] drugs, sequela
T38.4X5A Adverse effect of oral contraceptives, initial encounter
T38.4X5D Adverse effect of oral contraceptives, subsequent encounter
T38.4X5S Adverse effect of oral contraceptives, sequela
T38.5X5A Adverse effect of other estrogens and progestogens, initial encounter
T38.5X5D Adverse effect of other estrogens and progestogens, subsequent encounter
T38.5X5S Adverse effect of other estrogens and progestogens, sequela
T38.6X5A Adverse effect of antigonadotrophins, antiestrogens, antiandrogens, not elsewhere classified, initial encounter
T38.6X5D Adverse effect of antigonadotrophins, antiestrogens, antiandrogens, not elsewhere classified, subsequent encounter
T38.6X5S Adverse effect of antigonadotrophins, antiestrogens, antiandrogens, not elsewhere classified, sequela
T38.7X5A Adverse effect of androgens and anabolic congeners, initial encounter
T38.7X5D Adverse effect of androgens and anabolic congeners, subsequent encounter
T38.7X5S Adverse effect of androgens and anabolic congeners, sequela
T38.815A Adverse effect of anterior pituitary [adenohypophyseal] hormones, initial encounter
T38.815D Adverse effect of anterior pituitary [adenohypophyseal] hormones, subsequent encounter
T38.815S Adverse effect of anterior pituitary [adenohypophyseal] hormones, sequela
T38.895A Adverse effect of other hormones and synthetic substitutes, initial encounter
T38.895D Adverse effect of other hormones and synthetic substitutes, subsequent encounter
T38.895S Adverse effect of other hormones and synthetic substitutes, sequela
T38.995A Adverse effect of other hormone antagonists, initial encounter
T38.995D Adverse effect of other hormone antagonists, subsequent encounter
T38.995S Adverse effect of other hormone antagonists, sequela
T39.015A Adverse effect of aspirin, initial encounter
T39.015D Adverse effect of aspirin, subsequent encounter
T39.015S Adverse effect of aspirin, sequela
T39.095A Adverse effect of salicylates, initial encounter
T39.095D Adverse effect of salicylates, subsequent encounter
T39.095S Adverse effect of salicylates, sequela
T39.1X5A Adverse effect of 4-Aminophenol derivatives, initial encounter
T39.1X5D Adverse effect of 4-Aminophenol derivatives, subsequent encounter
T39.1X5S Adverse effect of 4-Aminophenol derivatives, sequela
T39.2X5A Adverse effect of pyrazolone derivatives, initial encounter
T39.2X5D Adverse effect of pyrazolone derivatives, subsequent encounter
T39.2X5S Adverse effect of pyrazolone derivatives, sequela
T39.315A Adverse effect of propionic acid derivatives, initial encounter
T39.315D Adverse effect of propionic acid derivatives, subsequent encounter
T39.315S Adverse effect of propionic acid derivatives, sequela
T39.395A Adverse effect of other nonsteroidal anti-inflammatory drugs [NSAID], initial encounter
T39.395D Adverse effect of other nonsteroidal anti-inflammatory drugs [NSAID], subsequent encounter
T39.395S Adverse effect of other nonsteroidal anti-inflammatory drugs [NSAID], sequela
T39.4X5A Adverse effect of antirheumatics, not elsewhere classified, initial encounter
T39.4X5D Adverse effect of antirheumatics, not elsewhere classified, subsequent encounter
T39.4X5S Adverse effect of antirheumatics, not elsewhere classified, sequela
T39.8X5A Adverse effect of other nonopioid analgesics and antipyretics, not elsewhere classified, initial encounter
T39.8X5D Adverse effect of other nonopioid analgesics and antipyretics, not elsewhere classified, subsequent encounter
T39.8X5S Adverse effect of other nonopioid analgesics and antipyretics, not elsewhere classified, sequela
T40.0X5A Adverse effect of opium, initial encounter
T40.0X5D Adverse effect of opium, subsequent encounter
T40.0X5S Adverse effect of opium, sequela
T40.2X5A Adverse effect of other opioids, initial encounter
T40.2X5D Adverse effect of other opioids, subsequent encounter
T40.2X5S Adverse effect of other opioids, sequela
T40.3X5A Adverse effect of methadone, initial encounter
T40.3X5D Adverse effect of methadone, subsequent encounter
T40.3X5S Adverse effect of methadone, sequela
T40.415A Adverse effect of fentanyl or fentanyl analogs, initial encounter
T40.415D Adverse effect of fentanyl or fentanyl analogs, subsequent encounter
T40.415S Adverse effect of fentanyl or fentanyl analogs, sequela
T40.425A Adverse effect of tramadol, initial encounter
T40.425D Adverse effect of tramadol, subsequent encounter
T40.425S Adverse effect of tramadol, sequela
T40.495A Adverse effect of other synthetic narcotics, initial encounter
T40.495D Adverse effect of other synthetic narcotics, subsequent encounter
T40.495S Adverse effect of other synthetic narcotics, sequela
T40.5X5A Adverse effect of cocaine, initial encounter
T40.5X5D Adverse effect of cocaine, subsequent encounter
T40.5X5S Adverse effect of cocaine, sequela
T40.695A Adverse effect of other narcotics, initial encounter
T40.695D Adverse effect of other narcotics, subsequent encounter
T40.695S Adverse effect of other narcotics, sequela
T40.715A Adverse effect of cannabis, initial encounter
T40.715D Adverse effect of cannabis, subsequent encounter
T40.715S Adverse effect of cannabis, sequela
T40.725A Adverse effect of synthetic cannabinoids, initial encounter
T40.725D Adverse effect of synthetic cannabinoids, subsequent encounter
T40.725S Adverse effect of synthetic cannabinoids, sequela
T40.995A Adverse effect of other psychodysleptics [hallucinogens], initial encounter
T40.995D Adverse effect of other psychodysleptics [hallucinogens], subsequent encounter
T40.995S Adverse effect of other psychodysleptics [hallucinogens], sequela
T41.0X5A Adverse effect of inhaled anesthetics, initial encounter
T41.0X5D Adverse effect of inhaled anesthetics, subsequent encounter
T41.0X5S Adverse effect of inhaled anesthetics, sequela
T41.1X5A Adverse effect of intravenous anesthetics, initial encounter
T41.1X5D Adverse effect of intravenous anesthetics, subsequent encounter
T41.1X5S Adverse effect of intravenous anesthetics, sequela
T41.295A Adverse effect of other general anesthetics, initial encounter
T41.295D Adverse effect of other general anesthetics, subsequent encounter
T41.295S Adverse effect of other general anesthetics, sequela
T41.3X5A Adverse effect of local anesthetics, initial encounter
T41.3X5D Adverse effect of local anesthetics, subsequent encounter
T41.3X5S Adverse effect of local anesthetics, sequela
T41.5X5A Adverse effect of therapeutic gases, initial encounter
T41.5X5D Adverse effect of therapeutic gases, subsequent encounter
T41.5X5S Adverse effect of therapeutic gases, sequela
T42.0X5A Adverse effect of hydantoin derivatives, initial encounter
T42.0X5D Adverse effect of hydantoin derivatives, subsequent encounter
T42.0X5S Adverse effect of hydantoin derivatives, sequela
T42.1X5A Adverse effect of iminostilbenes, initial encounter
T42.1X5D Adverse effect of iminostilbenes, subsequent encounter
T42.1X5S Adverse effect of iminostilbenes, sequela
T42.2X5A Adverse effect of succinimides and oxazolidinediones, initial encounter
T42.2X5D Adverse effect of succinimides and oxazolidinediones, subsequent encounter
T42.2X5S Adverse effect of succinimides and oxazolidinediones, sequela
T42.3X5A Adverse effect of barbiturates, initial encounter
T42.3X5D Adverse effect of barbiturates, subsequent encounter
T42.3X5S Adverse effect of barbiturates, sequela
T42.4X5A Adverse effect of benzodiazepines, initial encounter
T42.4X5D Adverse effect of benzodiazepines, subsequent encounter
T42.4X5S Adverse effect of benzodiazepines, sequela
T42.5X5A Adverse effect of mixed antiepileptics, initial encounter
T42.5X5D Adverse effect of mixed antiepileptics, subsequent encounter
T42.5X5S Adverse effect of mixed antiepileptics, sequela
T42.6X5A Adverse effect of other antiepileptic and sedative-hypnotic drugs, initial encounter
T42.6X5D Adverse effect of other antiepileptic and sedative-hypnotic drugs, subsequent encounter
T42.6X5S Adverse effect of other antiepileptic and sedative-hypnotic drugs, sequela
T42.8X5A Adverse effect of antiparkinsonism drugs and other central muscle-tone depressants, initial encounter
T42.8X5D Adverse effect of antiparkinsonism drugs and other central muscle-tone depressants, subsequent encounter
T42.8X5S Adverse effect of antiparkinsonism drugs and other central muscle-tone depressants, sequela
T43.015A Adverse effect of tricyclic antidepressants, initial encounter
T43.015D Adverse effect of tricyclic antidepressants, subsequent encounter
T43.015S Adverse effect of tricyclic antidepressants, sequela
T43.025A Adverse effect of tetracyclic antidepressants, initial encounter
T43.025D Adverse effect of tetracyclic antidepressants, subsequent encounter
T43.025S Adverse effect of tetracyclic antidepressants, sequela
T43.1X5A Adverse effect of monoamine-oxidase-inhibitor antidepressants, initial encounter
T43.1X5D Adverse effect of monoamine-oxidase-inhibitor antidepressants, subsequent encounter
T43.1X5S Adverse effect of monoamine-oxidase-inhibitor antidepressants, sequela
T43.215A Adverse effect of selective serotonin and norepinephrine reuptake inhibitors, initial encounter
T43.215D Adverse effect of selective serotonin and norepinephrine reuptake inhibitors, subsequent encounter
T43.215S Adverse effect of selective serotonin and norepinephrine reuptake inhibitors, sequela
T43.225A Adverse effect of selective serotonin reuptake inhibitors, initial encounter
T43.225D Adverse effect of selective serotonin reuptake inhibitors, subsequent encounter
T43.225S Adverse effect of selective serotonin reuptake inhibitors, sequela
T43.295A Adverse effect of other antidepressants, initial encounter
T43.295D Adverse effect of other antidepressants, subsequent encounter
T43.295S Adverse effect of other antidepressants, sequela
T43.3X5A Adverse effect of phenothiazine antipsychotics and neuroleptics, initial encounter
T43.3X5D Adverse effect of phenothiazine antipsychotics and neuroleptics, subsequent encounter
T43.3X5S Adverse effect of phenothiazine antipsychotics and neuroleptics, sequela
T43.4X5A Adverse effect of butyrophenone and thiothixene neuroleptics, initial encounter
T43.4X5D Adverse effect of butyrophenone and thiothixene neuroleptics, subsequent encounter
T43.4X5S Adverse effect of butyrophenone and thiothixene neuroleptics, sequela
T43.595A Adverse effect of other antipsychotics and neuroleptics, initial encounter
T43.595D Adverse effect of other antipsychotics and neuroleptics, subsequent encounter
T43.595S Adverse effect of other antipsychotics and neuroleptics, sequela
T43.615A Adverse effect of caffeine, initial encounter
T43.615D Adverse effect of caffeine, subsequent encounter
T43.615S Adverse effect of caffeine, sequela
T43.625A Adverse effect of amphetamines, initial encounter
T43.625D Adverse effect of amphetamines, subsequent encounter
T43.625S Adverse effect of amphetamines, sequela
T43.635A Adverse effect of methylphenidate, initial encounter
T43.635D Adverse effect of methylphenidate, subsequent encounter
T43.635S Adverse effect of methylphenidate, sequela
T43.655A Adverse effect of methamphetamines, initial encounter
T43.655D Adverse effect of methamphetamines, subsequent encounter
T43.655S Adverse effect of methamphetamines, sequela
T43.695A Adverse effect of other psychostimulants, initial encounter
T43.695D Adverse effect of other psychostimulants, subsequent encounter
T43.695S Adverse effect of other psychostimulants, sequela
T43.8X5A Adverse effect of other psychotropic drugs, initial encounter
T43.8X5D Adverse effect of other psychotropic drugs, subsequent encounter
T43.8X5S Adverse effect of other psychotropic drugs, sequela
T44.0X5A Adverse effect of anticholinesterase agents, initial encounter
T44.0X5D Adverse effect of anticholinesterase agents, subsequent encounter
T44.0X5S Adverse effect of anticholinesterase agents, sequela
T44.1X5A Adverse effect of other parasympathomimetics [cholinergics], initial encounter
T44.1X5D Adverse effect of other parasympathomimetics [cholinergics], subsequent encounter
T44.1X5S Adverse effect of other parasympathomimetics [cholinergics], sequela
T44.2X5A Adverse effect of ganglionic blocking drugs, initial encounter
T44.2X5D Adverse effect of ganglionic blocking drugs, subsequent encounter
T44.2X5S Adverse effect of ganglionic blocking drugs, sequela
T44.3X5A Adverse effect of other parasympatholytics [anticholinergics and antimuscarinics] and spasmolytics, initial encounter
T44.3X5D Adverse effect of other parasympatholytics [anticholinergics and antimuscarinics] and spasmolytics, subsequent encounter
T44.3X5S Adverse effect of other parasympatholytics [anticholinergics and antimuscarinics] and spasmolytics, sequela
T44.4X5A Adverse effect of predominantly alpha-adrenoreceptor agonists, initial encounter
T44.4X5D Adverse effect of predominantly alpha-adrenoreceptor agonists, subsequent encounter
T44.4X5S Adverse effect of predominantly alpha-adrenoreceptor agonists, sequela
T44.5X5A Adverse effect of predominantly beta-adrenoreceptor agonists, initial encounter
T44.5X5D Adverse effect of predominantly beta-adrenoreceptor agonists, subsequent encounter
T44.5X5S Adverse effect of predominantly beta-adrenoreceptor agonists, sequela
T44.6X5A Adverse effect of alpha-adrenoreceptor antagonists, initial encounter
T44.6X5D Adverse effect of alpha-adrenoreceptor antagonists, subsequent encounter
T44.6X5S Adverse effect of alpha-adrenoreceptor antagonists, sequela
T44.7X5A Adverse effect of beta-adrenoreceptor antagonists, initial encounter
T44.7X5D Adverse effect of beta-adrenoreceptor antagonists, subsequent encounter
T44.7X5S Adverse effect of beta-adrenoreceptor antagonists, sequela
T44.8X5A Adverse effect of centrally-acting and adrenergic-neuron-blocking agents, initial encounter
T44.8X5D Adverse effect of centrally-acting and adrenergic-neuron-blocking agents, subsequent encounter
T44.8X5S Adverse effect of centrally-acting and adrenergic-neuron-blocking agents, sequela
T44.995A Adverse effect of other drug primarily affecting the autonomic nervous system, initial encounter
T44.995D Adverse effect of other drug primarily affecting the autonomic nervous system, subsequent encounter
T44.995S Adverse effect of other drug primarily affecting the autonomic nervous system, sequela
T45.0X5A Adverse effect of antiallergic and antiemetic drugs, initial encounter
T45.0X5D Adverse effect of antiallergic and antiemetic drugs, subsequent encounter
T45.0X5S Adverse effect of antiallergic and antiemetic drugs, sequela
T45.1X5A Adverse effect of antineoplastic and immunosuppressive drugs, initial encounter
T45.1X5D Adverse effect of antineoplastic and immunosuppressive drugs, subsequent encounter
T45.1X5S Adverse effect of antineoplastic and immunosuppressive drugs, sequela
T45.2X5A Adverse effect of vitamins, initial encounter
T45.2X5D Adverse effect of vitamins, subsequent encounter
T45.2X5S Adverse effect of vitamins, sequela
T45.3X5A Adverse effect of enzymes, initial encounter
T45.3X5D Adverse effect of enzymes, subsequent encounter
T45.3X5S Adverse effect of enzymes, sequela
T45.4X5A Adverse effect of iron and its compounds, initial encounter
T45.4X5D Adverse effect of iron and its compounds, subsequent encounter
T45.4X5S Adverse effect of iron and its compounds, sequela
T45.515A Adverse effect of anticoagulants, initial encounter
T45.515D Adverse effect of anticoagulants, subsequent encounter
T45.515S Adverse effect of anticoagulants, sequela
T45.525A Adverse effect of antithrombotic drugs, initial encounter
T45.525D Adverse effect of antithrombotic drugs, subsequent encounter
T45.525S Adverse effect of antithrombotic drugs, sequela
T45.605A Adverse effect of unspecified fibrinolysis-affecting drugs, initial encounter
T45.605D Adverse effect of unspecified fibrinolysis-affecting drugs, subsequent encounter
T45.605S Adverse effect of unspecified fibrinolysis-affecting drugs, sequela
T45.615A Adverse effect of thrombolytic drugs, initial encounter
T45.615D Adverse effect of thrombolytic drugs, subsequent encounter
T45.615S Adverse effect of thrombolytic drugs, sequela
T45.625A Adverse effect of hemostatic drug, initial encounter
T45.625D Adverse effect of hemostatic drug, subsequent encounter
T45.625S Adverse effect of hemostatic drug, sequela
T45.695A Adverse effect of other fibrinolysis-affecting drugs, initial encounter
T45.695D Adverse effect of other fibrinolysis-affecting drugs, subsequent encounter
T45.695S Adverse effect of other fibrinolysis-affecting drugs, sequela
T45.7X5A Adverse effect of anticoagulant antagonists, vitamin K and other coagulants, initial encounter
T45.7X5D Adverse effect of anticoagulant antagonists, vitamin K and other coagulants, subsequent encounter
T45.7X5S Adverse effect of anticoagulant antagonists, vitamin K and other coagulants, sequela
T45.8X5A Adverse effect of other primarily systemic and hematological agents, initial encounter
T45.8X5D Adverse effect of other primarily systemic and hematological agents, subsequent encounter
T45.8X5S Adverse effect of other primarily systemic and hematological agents, sequela
T45.AX5A Adverse effect of immune checkpoint inhibitors and immunostimulant drugs, initial encounter
T45.AX5D Adverse effect of immune checkpoint inhibitors and immunostimulant drugs, subsequent encounter
T45.AX5S Adverse effect of immune checkpoint inhibitors and immunostimulant drugs, sequela
T46.0X5A Adverse effect of cardiac-stimulant glycosides and drugs of similar action, initial encounter
T46.0X5D Adverse effect of cardiac-stimulant glycosides and drugs of similar action, subsequent encounter
T46.0X5S Adverse effect of cardiac-stimulant glycosides and drugs of similar action, sequela
T46.1X5A Adverse effect of calcium-channel blockers, initial encounter
T46.1X5D Adverse effect of calcium-channel blockers, subsequent encounter
T46.1X5S Adverse effect of calcium-channel blockers, sequela
T46.2X5A Adverse effect of other antidysrhythmic drugs, initial encounter
T46.2X5D Adverse effect of other antidysrhythmic drugs, subsequent encounter
T46.2X5S Adverse effect of other antidysrhythmic drugs, sequela
T46.3X5A Adverse effect of coronary vasodilators, initial encounter
T46.3X5D Adverse effect of coronary vasodilators, subsequent encounter
T46.3X5S Adverse effect of coronary vasodilators, sequela
T46.4X5A Adverse effect of angiotensin-converting-enzyme inhibitors, initial encounter
T46.4X5D Adverse effect of angiotensin-converting-enzyme inhibitors, subsequent encounter
T46.4X5S Adverse effect of angiotensin-converting-enzyme inhibitors, sequela
T46.5X5A Adverse effect of other antihypertensive drugs, initial encounter
T46.5X5D Adverse effect of other antihypertensive drugs, subsequent encounter
T46.5X5S Adverse effect of other antihypertensive drugs, sequela
T46.6X5A Adverse effect of antihyperlipidemic and antiarteriosclerotic drugs, initial encounter
T46.6X5D Adverse effect of antihyperlipidemic and antiarteriosclerotic drugs, subsequent encounter
T46.6X5S Adverse effect of antihyperlipidemic and antiarteriosclerotic drugs, sequela
T46.7X5A Adverse effect of peripheral vasodilators, initial encounter
T46.7X5D Adverse effect of peripheral vasodilators, subsequent encounter
T46.7X5S Adverse effect of peripheral vasodilators, sequela
T46.8X5A Adverse effect of antivaricose drugs, including sclerosing agents, initial encounter
T46.8X5D Adverse effect of antivaricose drugs, including sclerosing agents, subsequent encounter
T46.8X5S Adverse effect of antivaricose drugs, including sclerosing agents, sequela
T46.995A Adverse effect of other agents primarily affecting the cardiovascular system, initial encounter
T46.995D Adverse effect of other agents primarily affecting the cardiovascular system, subsequent encounter
T46.995S Adverse effect of other agents primarily affecting the cardiovascular system, sequela
T47.0X5A Adverse effect of histamine H2-receptor blockers, initial encounter
T47.0X5D Adverse effect of histamine H2-receptor blockers, subsequent encounter
T47.0X5S Adverse effect of histamine H2-receptor blockers, sequela
T47.1X5A Adverse effect of other antacids and anti-gastric-secretion drugs, initial encounter
T47.1X5D Adverse effect of other antacids and anti-gastric-secretion drugs, subsequent encounter
T47.1X5S Adverse effect of other antacids and anti-gastric-secretion drugs, sequela
T47.2X5A Adverse effect of stimulant laxatives, initial encounter
T47.2X5D Adverse effect of stimulant laxatives, subsequent encounter
T47.2X5S Adverse effect of stimulant laxatives, sequela
T47.3X5A Adverse effect of saline and osmotic laxatives, initial encounter
T47.3X5D Adverse effect of saline and osmotic laxatives, subsequent encounter
T47.3X5S Adverse effect of saline and osmotic laxatives, sequela
T47.4X5A Adverse effect of other laxatives, initial encounter
T47.4X5D Adverse effect of other laxatives, subsequent encounter
T47.4X5S Adverse effect of other laxatives, sequela
T47.5X5A Adverse effect of digestants, initial encounter
T47.5X5D Adverse effect of digestants, subsequent encounter
T47.5X5S Adverse effect of digestants, sequela
T47.6X5A Adverse effect of antidiarrheal drugs, initial encounter
T47.6X5D Adverse effect of antidiarrheal drugs, subsequent encounter
T47.6X5S Adverse effect of antidiarrheal drugs, sequela
T47.7X5A Adverse effect of emetics, initial encounter
T47.7X5D Adverse effect of emetics, subsequent encounter
T47.7X5S Adverse effect of emetics, sequela
T47.8X5A Adverse effect of other agents primarily affecting gastrointestinal system, initial encounter
T47.8X5D Adverse effect of other agents primarily affecting gastrointestinal system, subsequent encounter
T47.8X5S Adverse effect of other agents primarily affecting gastrointestinal system, sequela
T48.0X5A Adverse effect of oxytocic drugs, initial encounter
T48.0X5D Adverse effect of oxytocic drugs, subsequent encounter
T48.0X5S Adverse effect of oxytocic drugs, sequela
T48.1X5A Adverse effect of skeletal muscle relaxants [neuromuscular blocking agents], initial encounter
T48.1X5D Adverse effect of skeletal muscle relaxants [neuromuscular blocking agents], subsequent encounter
T48.1X5S Adverse effect of skeletal muscle relaxants [neuromuscular blocking agents], sequela
T48.295A Adverse effect of other drugs acting on muscles, initial encounter
T48.295D Adverse effect of other drugs acting on muscles, subsequent encounter
T48.295S Adverse effect of other drugs acting on muscles, sequela
T48.3X5A Adverse effect of antitussives, initial encounter
T48.3X5D Adverse effect of antitussives, subsequent encounter
T48.3X5S Adverse effect of antitussives, sequela
T48.4X5A Adverse effect of expectorants, initial encounter
T48.4X5D Adverse effect of expectorants, subsequent encounter
T48.4X5S Adverse effect of expectorants, sequela
T48.5X5A Adverse effect of other anti-common-cold drugs, initial encounter
T48.5X5D Adverse effect of other anti-common-cold drugs, subsequent encounter
T48.5X5S Adverse effect of other anti-common-cold drugs, sequela
T48.6X5A Adverse effect of antiasthmatics, initial encounter
T48.6X5D Adverse effect of antiasthmatics, subsequent encounter
T48.6X5S Adverse effect of antiasthmatics, sequela
T48.995A Adverse effect of other agents primarily acting on the respiratory system, initial encounter
T48.995D Adverse effect of other agents primarily acting on the respiratory system, subsequent encounter
T48.995S Adverse effect of other agents primarily acting on the respiratory system, sequela
T49.0X5A Adverse effect of local antifungal, anti-infective and anti-inflammatory drugs, initial encounter
T49.0X5D Adverse effect of local antifungal, anti-infective and anti-inflammatory drugs, subsequent encounter
T49.0X5S Adverse effect of local antifungal, anti-infective and anti-inflammatory drugs, sequela
T49.1X5A Adverse effect of antipruritics, initial encounter
T49.1X5D Adverse effect of antipruritics, subsequent encounter
T49.1X5S Adverse effect of antipruritics, sequela
T49.6X5A Adverse effect of otorhinolaryngological drugs and preparations, initial encounter
T49.6X5D Adverse effect of otorhinolaryngological drugs and preparations, subsequent encounter
T49.6X5S Adverse effect of otorhinolaryngological drugs and preparations, sequela
T49.7X5A Adverse effect of dental drugs, topically applied, initial encounter
T49.7X5D Adverse effect of dental drugs, topically applied, subsequent encounter
T49.7X5S Adverse effect of dental drugs, topically applied, sequela
T50.0X5A Adverse effect of mineralocorticoids and their antagonists, initial encounter
T50.0X5D Adverse effect of mineralocorticoids and their antagonists, subsequent encounter
T50.0X5S Adverse effect of mineralocorticoids and their antagonists, sequela
T50.1X5A Adverse effect of loop [high-ceiling] diuretics, initial encounter
T50.1X5D Adverse effect of loop [high-ceiling] diuretics, subsequent encounter
T50.1X5S Adverse effect of loop [high-ceiling] diuretics, sequela
T50.2X5A Adverse effect of carbonic-anhydrase inhibitors, benzothiadiazides and other diuretics, initial encounter
T50.2X5D Adverse effect of carbonic-anhydrase inhibitors, benzothiadiazides and other diuretics, subsequent encounter
T50.2X5S Adverse effect of carbonic-anhydrase inhibitors, benzothiadiazides and other diuretics, sequela
T50.3X5A Adverse effect of electrolytic, caloric and water-balance agents, initial encounter
T50.3X5D Adverse effect of electrolytic, caloric and water-balance agents, subsequent encounter
T50.3X5S Adverse effect of electrolytic, caloric and water-balance agents, sequela
T50.4X5A Adverse effect of drugs affecting uric acid metabolism, initial encounter
T50.4X5D Adverse effect of drugs affecting uric acid metabolism, subsequent encounter
T50.4X5S Adverse effect of drugs affecting uric acid metabolism, sequela
T50.5X5A Adverse effect of appetite depressants, initial encounter
T50.5X5D Adverse effect of appetite depressants, subsequent encounter
T50.5X5S Adverse effect of appetite depressants, sequela
T50.6X5A Adverse effect of antidotes and chelating agents, initial encounter
T50.6X5D Adverse effect of antidotes and chelating agents, subsequent encounter
T50.6X5S Adverse effect of antidotes and chelating agents, sequela
T50.7X5A Adverse effect of analeptics and opioid receptor antagonists, initial encounter
T50.7X5D Adverse effect of analeptics and opioid receptor antagonists, subsequent encounter
T50.7X5S Adverse effect of analeptics and opioid receptor antagonists, sequela
T50.8X5A Adverse effect of diagnostic agents, initial encounter
T50.8X5D Adverse effect of diagnostic agents, subsequent encounter
T50.8X5S Adverse effect of diagnostic agents, sequela
T50.B95A Adverse effect of other viral vaccines, initial encounter
T50.B95D Adverse effect of other viral vaccines, subsequent encounter
T50.B95S Adverse effect of other viral vaccines, sequela
T50.Z95A Adverse effect of other vaccines and biological substances, initial encounter
T50.Z95D Adverse effect of other vaccines and biological substances, subsequent encounter
T50.Z95S Adverse effect of other vaccines and biological substances, sequela
T78.01XA Anaphylactic reaction due to peanuts, initial encounter
T78.01XD Anaphylactic reaction due to peanuts, subsequent encounter
T78.01XS Anaphylactic reaction due to peanuts, sequela
T78.02XA Anaphylactic reaction due to shellfish (crustaceans), initial encounter
T78.02XD Anaphylactic reaction due to shellfish (crustaceans), subsequent encounter
T78.02XS Anaphylactic reaction due to shellfish (crustaceans), sequela
T78.03XA Anaphylactic reaction due to other fish, initial encounter
T78.03XD Anaphylactic reaction due to other fish, subsequent encounter
T78.03XS Anaphylactic reaction due to other fish, sequela
T78.04XA Anaphylactic reaction due to fruits and vegetables, initial encounter
T78.04XD Anaphylactic reaction due to fruits and vegetables, subsequent encounter
T78.04XS Anaphylactic reaction due to fruits and vegetables, sequela
T78.05XA Anaphylactic reaction due to tree nuts and seeds, initial encounter
T78.05XD Anaphylactic reaction due to tree nuts and seeds, subsequent encounter
T78.05XS Anaphylactic reaction due to tree nuts and seeds, sequela
T78.06XA Anaphylactic reaction due to food additives, initial encounter
T78.06XD Anaphylactic reaction due to food additives, subsequent encounter
T78.06XS Anaphylactic reaction due to food additives, sequela
T78.070A Anaphylactic reaction due to milk and dairy products with tolerance to baked milk, initial encounter
T78.070D Anaphylactic reaction due to milk and dairy products with tolerance to baked milk, subsequent encounter
T78.070S Anaphylactic reaction due to milk and dairy products with tolerance to baked milk, sequela
T78.071A Anaphylactic reaction due to milk and dairy products with reactivity to baked milk, initial encounter
T78.071D Anaphylactic reaction due to milk and dairy products with reactivity to baked milk, subsequent encounter
T78.071S Anaphylactic reaction due to milk and dairy products with reactivity to baked milk, sequela
T78.079A Anaphylactic reaction due to milk and dairy products, unspecified, initial encounter
T78.079D Anaphylactic reaction due to milk and dairy products, unspecified, subsequent encounter
T78.079S Anaphylactic reaction due to milk and dairy products, unspecified, sequela
T78.080A Anaphylactic reaction due to egg with tolerance to baked egg, initial encounter
T78.080D Anaphylactic reaction due to egg with tolerance to baked egg, subsequent encounter
T78.080S Anaphylactic reaction due to egg with tolerance to baked egg, sequela
T78.081A Anaphylactic reaction due to egg with reactivity to baked egg, initial encounter
T78.081D Anaphylactic reaction due to egg with reactivity to baked egg, subsequent encounter
T78.081S Anaphylactic reaction due to egg with reactivity to baked egg, sequela
T78.089A Anaphylactic reaction due to eggs, unspecified, initial encounter
T78.089D Anaphylactic reaction due to eggs, unspecified, subsequent encounter
T78.089S Anaphylactic reaction due to eggs, unspecified, sequela
T78.09XA Anaphylactic reaction due to other food products, initial encounter
T78.09XD Anaphylactic reaction due to other food products, subsequent encounter
T78.09XS Anaphylactic reaction due to other food products, sequela
T78.110A Other adverse food reactions due to milk and dairy products with tolerance to baked milk, initial encounter
T78.110D Other adverse food reactions due to milk and dairy products with tolerance to baked milk, subsequent encounter
T78.110S Other adverse food reactions due to milk and dairy products with tolerance to baked milk, sequela
T78.111A Other adverse food reaction due to milk and dairy products with reactivity to baked milk, initial encounter
T78.111D Other adverse food reaction due to milk and dairy products with reactivity to baked milk, subsequent encounter
T78.111S Other adverse food reaction due to milk and dairy products with reactivity to baked milk, sequela
T78.119A Other adverse food reaction due to milk and dairy products with baked milk tolerance/reactivity, unspecified, initial encounter
T78.119D Other adverse food reaction due to milk and dairy products with baked milk tolerance/reactivity, unspecified, subsequent encounter
T78.119S Other adverse food reaction due to milk and dairy products with baked milk tolerance/reactivity, unspecified, sequela
T78.120A Other adverse food reaction due to egg with tolerance to baked egg, initial encounter
T78.120D Other adverse food reaction due to egg with tolerance to baked egg, subsequent encounter
T78.120S Other adverse food reaction due to egg with tolerance to baked egg, sequela
T78.121A Other adverse food reaction due to egg with reactivity to baked egg, initial encounter
T78.121D Other adverse food reaction due to egg with reactivity to baked egg, subsequent encounter
T78.121S Other adverse food reaction due to egg with reactivity to baked egg, sequela
T78.129A Other adverse food reaction due to egg with baked egg tolerance/reactivity, unspecified, initial encounter
T78.129D Other adverse food reaction due to egg with baked egg tolerance/reactivity, unspecified, subsequent encounter
T78.129S Other adverse food reaction due to egg with baked egg tolerance/reactivity, unspecified, sequela
T78.3XXA Angioneurotic edema, initial encounter
T78.3XXD Angioneurotic edema, subsequent encounter
T78.3XXS Angioneurotic edema, sequela
T78.49XA Other allergy, initial encounter
T78.49XD Other allergy, subsequent encounter
T78.49XS Other allergy, sequela

Group 4

(26 Codes)
Group 4 Paragraph

The following ICD-10-CM codes may be used as secondary diagnoses for reporting additional information only.

Group 4 Codes
Code Description
Z88.0 Allergy status to penicillin
Z88.1 Allergy status to other antibiotic agents
Z88.2 Allergy status to sulfonamides
Z88.3 Allergy status to other anti-infective agents
Z88.4 Allergy status to anesthetic agent
Z88.5 Allergy status to narcotic agent
Z88.6 Allergy status to analgesic agent
Z88.7 Allergy status to serum and vaccine
Z88.8 Allergy status to other drugs, medicaments and biological substances
Z91.010 Allergy to peanuts
Z91.0110 Allergy to milk products, unspecified
Z91.0111 Allergy to milk products with tolerance to baked milk
Z91.0112 Allergy to milk products with reactivity to baked milk
Z91.0120 Allergy to eggs, unspecified
Z91.0121 Allergy to eggs with tolerance to baked egg
Z91.0122 Allergy to eggs with reactivity to baked egg
Z91.013 Allergy to seafood
Z91.014 Allergy to mammalian meats
Z91.018 Allergy to other foods
Z91.02 Food additives allergy status
Z91.030 Bee allergy status
Z91.038 Other insect allergy status
Z91.040 Latex allergy status
Z91.041 Radiographic dye allergy status
Z91.048 Other nonmedicinal substance allergy status
Z91.09 Other allergy status, other than to drugs and biological substances
N/A

ICD-10-CM Codes that DO NOT Support Medical Necessity

Group 1

Group 1 Paragraph

N/A

Group 1 Codes

N/A

N/A

ICD-10-PCS Codes

Group 1

Group 1 Paragraph

N/A

Group 1 Codes

N/A

N/A

Additional ICD-10 Information

N/A

Bill Type Codes

Contractors may specify Bill Types to help providers identify those Bill Types typically used to report this service. Absence of a Bill Type does not guarantee that the article does not apply to that Bill Type. Complete absence of all Bill Types indicates that coverage is not influenced by Bill Type and the article should be assumed to apply equally to all claims.

Code Description

Please accept the License to see the codes.

N/A

Revenue Codes

Contractors may specify Revenue Codes to help providers identify those Revenue Codes typically used to report this service. In most instances Revenue Codes are purely advisory. Unless specified in the article, services reported under other Revenue Codes are equally subject to this coverage determination. Complete absence of all Revenue Codes indicates that coverage is not influenced by Revenue Code and the article should be assumed to apply equally to all Revenue Codes.

Code Description

Please accept the License to see the codes.

N/A

Other Coding Information

Group 1

Group 1 Paragraph

N/A

Group 1 Codes

N/A

N/A

Coding Table Information

Excluded CPT/HCPCS Codes - Table Format
Code Descriptor Generic Name Descriptor Brand Name Exclusion Effective Date Exclusion End Date Reason for Exclusion
N/A N/A
N/A
Non-Excluded CPT/HCPCS Ended Codes - Table Format
Code Descriptor Generic Name Descriptor Brand Name Exclusion Effective Date Exclusion End Date Reason for Exclusion
N/A

Revision History Information

Revision History Date Revision History Number Revision History Explanation
N/A

Associated Documents

Medicare BPM Ch 15.50.2 SAD Determinations
Medicare BPM Ch 15.50.2
Related Local Coverage Documents
N/A
Related National Coverage Documents
NCDs
N/A
SAD Process URL 1
N/A
SAD Process URL 2
N/A
Statutory Requirements URLs
N/A
Rules and Regulations URLs
N/A
CMS Manual Explanations URLs
N/A
Other URLs
N/A
Public Versions
Updated On Archived Date Status
01/09/2026 N/A N/A You are here

Keywords

N/A